Rockefeller Capital Management
LEXX icon

Rockefeller Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Rockefeller Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$191 – 4771
2025
Q3 		$191 Buy
+13
New +$189 ﹤0.01% 4350

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Rockefeller Capital Management's LEXX Position: Q4 2025 in Review

Rockefeller Capital Management sold out of Lexaria Bioscience (LEXX) in Q4 2025, closing a stake of 13 shares — an estimated $191 sold.

Rockefeller Capital Management first reported a position in LEXX in Q3 2025 and held it in 1 quarter. The position peaked at $191 in Q3 2025. 20 funds tracked by Wall St. Rank hold LEXX as of Q4 2025.

  • Rockefeller Capital Management reported no remaining Lexaria Bioscience position as of Q4 2025 after selling out during the quarter.
  • Rockefeller Capital Management sold 13 Lexaria Bioscience shares in Q4 2025, an estimated $191.
  • Rockefeller Capital Management first reported a position in Lexaria Bioscience in Q3 2025 and held it in 1 quarter.
  • Rockefeller Capital Management's Lexaria Bioscience position peaked at $191 in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q4 2025.

Based on Rockefeller Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.